Literature DB >> 4008291

Changes in misonidazole binding with hypoxic fraction in mouse tumors.

D G Hirst, J L Hazlehurst, J M Brown.   

Abstract

Binding of misonidazole (MISO) or a derivative to hypoxic cells in tumors has been proposed as a method for identifying tumors and measuring their level of hypoxia. We have recently shown that the hypoxic fraction of tumor cells can be altered over a wide range in vivo by acutely changing the hematocrit of the host animal by transfusion. The present study aimed to investigate the changes in binding by 14C MISO that accompanied this procedure. Tumor bearing mice were injected with 14C MISO, irradiated with a single dose of X rays (20 Gy) and their tumor excised and bisected. One half of each tumor was used to determine cell survival in vitro, the other was used for 14C scintillation counting. As previously described, tumor cell survival was dramatically increased in acutely anemic mice and this was accompanied by an increase in 14C MISO binding to the tumors. The relationship between clonogenic cell survival and binding was found to be linear on a log-log plot for each of the tumor lines studied, but the slopes of the lines were different tumor lines and generally steeper than the value of 1.0 expected for a 1:1 correspondence between cells binding radioactivity and radiobiological resistance. We attribute these differences to MISO binding to cells in the tumor which were not clonogenic.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4008291     DOI: 10.1016/0360-3016(85)90251-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

Review 1.  Tumor hypoxia: its impact on cancer therapy.

Authors:  J E Moulder; S Rockwell
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  Radiosynthesis of [(131)I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker?

Authors:  Makiko Suehiro; Paul Burgman; Sean Carlin; Sean Burke; Guangbin Yang; Ouathek Ouerfelli; Christoph Oehler-Janne; Joseph O'Donoghue; Clifton Ling; John Humm
Journal:  Nucl Med Biol       Date:  2009-05-07       Impact factor: 2.408

3.  The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse.

Authors:  B Joiner; V K Hirst; S R McKeown; J J McAleer; D G Hirst
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

4.  Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours.

Authors:  J A Raleigh; G G Miller; A J Franko; C J Koch; A F Fuciarelli; D A Kelly
Journal:  Br J Cancer       Date:  1987-10       Impact factor: 7.640

5.  An enzyme-linked immunosorbent assay for hypoxia marker binding in tumours.

Authors:  J A Raleigh; J K La Dine; J M Cline; D E Thrall
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

6.  The effect of hypobaric hypoxia on misonidazole binding in normal and tumour-bearing mice.

Authors:  M P MacManus; A P Maxwell; W P Abram; J M Bridges
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.